Two vaccine projects against the Covid-19, a briton and a chinese, have produced a substantial immune response and demonstrated their safety for the patients, according to the results of two separate clinical trials, published Monday in the british medical journal The Lancet.
The first, developed by the university of Oxford in partnership with AstraZeneca, has generated a “strong immune response” in a trial on over 1,000 patients, while the second, supported by CanSino Biologics, has provoked a strong response in terms of antibody in another test at the most about 500 participants.
